Literature DB >> 21724929

Vancomycin: a 50-something-year-old antibiotic we still don't understand.

Amy Schilling1, Elizabeth Neuner, Susan J Rehm.   

Abstract

Because a significant proportion of Staphylococcus aureus strains as well as most coagulase-negative staphylococci are resistant to penicillin and semisynthetic beta-lactam drugs, the need for vancomycin and related antibiotics has never been greater. Effective use of vancomycin requires knowledge of dosing parameters and selection of target trough levels appropriate to the specific infection and to the pathogen being treated. For clinicians, it is vital to remain up-to-date with evolving definitions for vancomycin susceptibility, with new interpretations of efficacy, and with information on toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724929     DOI: 10.3949/ccjm.78a.10168

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  10 in total

1.  Identification of Synthetic and Natural Host Defense Peptides with Leishmanicidal Activity.

Authors:  A K Marr; S Cen; R E W Hancock; W R McMaster
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

2.  Can Nasal Methicillin-Resistant Staphylococcus aureus Screening Be Used to Avoid Empiric Vancomycin Use in Intra-Abdominal Infection?

Authors:  Sara A Hennessy; Puja M Shah; Christopher A Guidry; Stephen W Davies; Tjasa Hranjec; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2015-06-12       Impact factor: 2.150

3.  Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010.

Authors:  Y-H Chen; C-Y Liu; W-C Ko; C-H Liao; P-L Lu; C-H Huang; C-T Lu; Y-C Chuang; S-M Tsao; Y-S Chen; Y-C Liu; W-Y Chen; T-N Jang; H-C Lin; C-M Chen; Z-Y Shi; S-C Pan; J-L Yang; H-C Kung; C-E Liu; Y-J Cheng; J-W Liu; W Sun; L-S Wang; K-W Yu; P-C Chiang; M-H Lee; C-M Lee; G-J Hsu; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-18       Impact factor: 3.267

4.  Monitoring intraventricular vancomycin for ventriculostomy access device infection in preterm infants.

Authors:  Jaya Madhura Parasuraman; Mahableshwar Albur; Greg Fellows; Axel Heep
Journal:  Childs Nerv Syst       Date:  2017-10-24       Impact factor: 1.475

5.  Vancomycin dosing in an obese patient with acute renal failure: A case report and review of literature.

Authors:  Kun-Yan Xu; Dan Li; Zhen-Jie Hu; Cong-Cong Zhao; Jing Bai; Wen-Li Du
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

6.  Immunocytochemistry for vancomycin using a monoclonal antibody that reveals accumulation of the drug in rat kidney and liver.

Authors:  Kunio Fujiwara; Yohei Yoshizaki; Masashi Shin; Tsubasa Miyazaki; Tetsuya Saita; Shuichi Nagata
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

7.  Transport of Vancomycin and Cefepime Into Human Intervertebral Discs: Quantitative Analyses.

Authors:  Qiaoqiao Zhu; Xin Gao; Mark D Brown; Frank Eismont; Weiyong Gu
Journal:  Spine (Phila Pa 1976)       Date:  2019-09-01       Impact factor: 3.241

8.  Assessment of vancomycin utilization among Lebanese hospitals.

Authors:  Diana N Malaeb; Iqbal M Fahs; Pascale Salameh; Souheil Hallit; Manal Saad; Jassem Bourji; Rabih Hallit
Journal:  Saudi Med J       Date:  2019-02       Impact factor: 1.484

9.  Population Pharmacokinetics of Intraventricular Vancomycin in Neonatal Ventriculitis, A Preterm Pilot Study.

Authors:  Jaya Madhura Parasuraman; Frank Kloprogge; Joseph Frank Standing; Mahableshwar Albur; Axel Heep
Journal:  Eur J Pharm Sci       Date:  2020-11-12       Impact factor: 4.384

10.  The risk of vancomycin toxicity in patients with liver impairment.

Authors:  Luigi Brunetti; Jong Hwa Song; David Suh; Heui Jae Kim; Yeon Hee Seong; Dae Song Lee; Seung-Mi Lee; Dong-Churl Suh
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-03-31       Impact factor: 3.944

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.